Incorporating novel biomarkers like endostatin could enhance early risk stratification and AKI diagnosis, allowing timely intervention for reversible factors like hypoperfusion and nephrotoxic exposures, ultimately improving ICU outcomes. This evidence concerns the gene COL18A1 and acute kidney injury.